{"id":"tramacet-naloxone","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Itching"},{"rate":"5-10%","effect":"Sedation"},{"rate":"1-5% (with naloxone use)","effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tramadol's mechanism of action involves the inhibition of the reuptake of norepinephrine and serotonin, as well as the binding to opioid receptors. This results in the analgesic effect. Naloxone, on the other hand, works by competitively binding to opioid receptors, which reverses the effects of opioids and can restore breathing in individuals who have overdosed.","oneSentence":"Tramadol is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, while naloxone is an opioid antagonist that reverses opioid overdose by blocking opioid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:36.972Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to moderately severe pain"},{"name":"Opioid overdose reversal"}]},"trialDetails":[{"nctId":"NCT00679614","phase":"PHASE3","title":"Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Hip Arthroplasty, Knee Arthroplasty, Spinal Anesthesia","enrollment":45},{"nctId":"NCT00665262","phase":"PHASE4","title":"The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in the Elderly","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2007-12-17","conditions":"Arthroplasty","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tramadol/acetaminophen"],"phase":"phase_3","status":"active","brandName":"tramacet, naloxone","genericName":"tramacet, naloxone","companyName":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","companyId":"london-health-sciences-centre-research-institute-or-lawson-research-institute-of","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tramadol is a centrally acting opioid analgesic that works by binding to opioid receptors in the brain and spinal cord, while naloxone is an opioid antagonist that reverses opioid overdose by blocking opioid receptors. Used for Moderate to moderately severe pain, Opioid overdose reversal.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}